Active targeting schemes for nanoparticle systems in cancer therapeutics

Byrne, James D.; Betancourt, Tania; Brannon-Peppas, Lisa

doi:10.1016/j.addr.2008.08.005

Cited by 1,541 publications

(1,021 citation statements)

References 125 publications

Supporting

Mentioning

983

Contrasting

Unclassified

Order By: Relevance

“…(Utreja et al, 2010;Dinarvand et al, 2011) Cancer is the leading cause of death in economically developed countries and the second leading cause of death in developing countries (Mathers et al, 2008;Jemal et al, 2011). The World Health Organization estimates that 84 million people will die of cancer between 2005 and 2015 (Byrne et al, 2008;Danhier et al, 2010). Cancer research is a rigorous scientific attempt in order to recognize the causes and develop exact strategies for prevention, diagnosis and treatments.…”

Section: Plga Nanoparticles For Drug Delivery To Tumorsmentioning

confidence: 99%

“…Tumor hypoxia and oncogenes upregulate VEGF levels in the tumor cells, resulting in an upregulation of VEGF receptors on tumor endothelial cells. Two major approaches to object angiogenesis via the VEGF way have been studied: 1) targeting VEGFR-2 to reduce VEGF binding and induce an endocytotic pathway and 2) targeting VEGF to restrain ligand binding to VEGFR-2 (Carmeliet, 2005;Byrne et al, 2008;Danhier et al, 2010).…”

Section: Targeting Of Tumoral Endotheliummentioning

confidence: 99%

“…The αvβ3 integrin is extremely expressed on neovascular endothelial cells but poorly expressed in resting endothelial cells and most normal organs, and is significant in the calcium dependent signaling pathway leading to endothelial cell migration (Byrne et al, 2008;Danhier et al, 2010).…”

Section: Targeting Of Tumoral Endotheliummentioning

confidence: 99%

See 2 more Smart Citations

PLGA-Based Nanoparticles as Cancer Drug Delivery Systems

Mirakabad

Nejati-Koshki²,

Akbarzadeh³

et al. 2014

Asian Pacific Journal of Cancer Prevention

398

154

View full text Add to dashboard Cite

Section: Plga Nanoparticles For Drug Delivery To Tumorsmentioning

confidence: 99%

Section: Targeting Of Tumoral Endotheliummentioning

confidence: 99%

See 1 more Smart Citation

PLGA-Based Nanoparticles as Cancer Drug Delivery Systems

Mirakabad

Nejati-Koshki²,

Akbarzadeh³

et al. 2014

Asian Pacific Journal of Cancer Prevention

398

154

View full text Add to dashboard Cite

“…It has been reported that nanoparticle therapeutics can enhance anticancer efficacy, while reduce the side-effects, owing to properties including preferential accumulation in tumor tissue as a result of enhanced permeation and retention (EPR) effect (3) and active intracellular uptake (4). Nanosized self-assembled constructs, such as micelles, have shown many advantages as potential drug delivery systems (5,6).…”

Section: Introductionmentioning

confidence: 99%

Stability Influences the Biodistribution, Toxicity, and Anti-tumor Activity of Doxorubicin Encapsulated in PEG-PE Micelles in Mice

et al. 2012

View full text Add to dashboard Cite

Purpose To investigate the influences of stability of doxorubicin (DOX) retained in PEG-PE/HSPC micelles on its biodistribution, toxicity and anti-tumor activity in mice. Methods We incorporated HSPC into PEG-PE micelles at various molar ratios by a self-assembly procedure. Micelles were characterized by dynamic light scattering, transmission electron microscope, atomic force microscopy. Agarose gel electrophoresis assay was used to detect stable retention of DOX in micellar preparations. Biodistribution, toxicity and antitumor activity of doxorubicin encapsulated in PEG-PE/HSPC micelles in mice were investigated. Results HSPC incorporation not only changed the size and shape of PEG-PE micelles, but also decreased the ability of DOX stable retained in PEG-PE micelles, resulting in a great discrepancy in biodistribution, toxicity and anti-tumor activity among micellar DOX preparations. DOX encapsulated in PEG-PE micelles (M 1 -DOX), with narrower size distribution and greater stability, demonstrated better cytotoxicity in vitro and low systemic toxicity with superior anti-tumor metastasis activity in vivo. Conclusions Encapsulation of DOX into PEG-PE micelles showed the best therapeutic activity and lowest systemic toxicity compared to other HSPC-incorporated PEG-PE micellar preparations. Stable retention of drugs within micelles is important and is determined by compatibility between drugs and polymer blocks.

show abstract

“…Damage to this regulation can induce an uncontrolled cell growth [29], which leads to the emergence of a more efficient proliferating machinery that replicates the cell without control. Such cells over express altered surface molecules, which can become targets for nanoparticle-based systems equipped with antibodies (against surface peptides or glycoproteins), aptamers (against surface antigens), or specific ligands (for receptors) [30]. Cancer cell surface host molecules that are regularly selected for study are: (i) folate receptor; (ii) transferrin receptors; and (iii) endothelial receptors.…”

Section: Selection Through Uncontrolled Proliferationmentioning

confidence: 99%

The potential legacy of cancer nanotechnology: cellular selection

Patra

Turner

2014

Trends in Biotechnology

View full text Add to dashboard Cite

Overexpression of oncogenes or loss of tumour suppressors can transform a normal cell to a cancerous one, resulting in uncontrolled regulation of intracellular signaling pathways and immunity to stresses, which both pose therapeutic challenges.Conventional approaches to cancer therapy, although they are effective at killing cancer cells, may still fail due to inadequate biodistribution and unwanted side effects.Nanotechnology-based approaches provide a promising alternative, with the possibility of targeting cells at an early stage, during their transformation into cancer cells. This review considers techniques that specifically target those molecular changes, which begin in only a very small percentage of normal cells as they undergo transformation. These techniques are crucial for 'early-stage' diagnosis and therapy.3

show abstract

Active targeting schemes for nanoparticle systems in cancer therapeutics

Cited by 1,541 publications

References 125 publications

PLGA-Based Nanoparticles as Cancer Drug Delivery Systems

PLGA-Based Nanoparticles as Cancer Drug Delivery Systems

Stability Influences the Biodistribution, Toxicity, and Anti-tumor Activity of Doxorubicin Encapsulated in PEG-PE Micelles in Mice

The potential legacy of cancer nanotechnology: cellular selection

Contact Info

Product

Resources

About